ImQuest to develop therapeutics for Samjin

By Angela McDaniels

Seattle, Jan. 24 - ImQuest Pharmaceuticals Inc. and Samjin Pharmaceutical Co. Ltd. have formed a strategic drug development alliance, according to a company news release.

Under the terms of the agreement, ImQuest will provide preclinical and clinical drug development support for therapeutic small molecules discovered by Samjin.

"This relationship merges the significant individual strengths of both companies," ImQuest chief executive officer Jerry Cartright said in the release.

"Samjin's medicinal chemistry team will provide new entities that will be developed using ImQuest's preclinical and clinical development expertise. Initially, our efforts will be focused on the rapid development of novel infectious disease and cancer agents."

ImQuest is a privately held pharmaceutical company based in Frederick, Md., that develops novel therapeutic agents for the treatment of infectious disease, cancer and inflammatory disease.

Samjin is a pharmaceutical company based in Seoul, South Korea.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.